Emerging medical devices for minimally invasive cell therapy

Mayo Clinic Proceedings

Volumn 89, Issue 2, 2014, Pages 259-273

  O'Cearbhaill, Eoin D ^a,b,c,d,e   Ng, Kelvin S ^a,b,c,d   Karp, Jeffrey M ^a,b,c,d  

^a Center for Regenerative Medicine   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BALLOON CATHETER; CATHETER; CELL FUNCTION; CELL INFUSION DEVICE; CELL THERAPY; CELL VIABILITY; CLINICAL TRIAL (TOPIC); CORONARY ARTERY; COST; EMBOLIZATION COIL; ENCAPSULATION DEVICE; EQUIPMENT DESIGN; GUIDE WIRE; HUMAN; IN VIVO STUDY; INFUSION SYSTEM; MEDICAL DEVICE; MEDICAL DEVICE COMPLICATION; MINIMALLY INVASIVE PROCEDURE; NEEDLE; PANCREAS ISLET; POINT OF CARE TESTING; ROBOTICS; SAFETY; STUDY DESIGN; SYRINGE; BIOLOGICAL THERAPY; EQUIPMENT; FOOD AND DRUG ADMINISTRATION; INSULIN DEPENDENT DIABETES MELLITUS; IPSC; MESENCHYMAL STEM CELL; MSC; PERCUTANEOUS TRANSVENOUS TRANSPLANTATION OF AUTOLOGOUS MYOBLASTS IN THE TREATMENT OF POSTINFARCTION HEART FAILURE; PLURIPOTENT STEM CELL; POZNAN; REVIEW; T1D; TOPCARE-AMI; TRANSPLANTATION OF PROGENITOR CELLS AND REGENERATION ENHANCEMENT IN ACUTE MYOCARDIAL INFARCTION; U.S. FOOD AND DRUG ADMINISTRATION; UNITED STATES;

POLITEF;

FDA; INDUCED PLURIPOTENT STEM CELL; IPSC; MESENCHYMAL STEM CELL; MSC; PERCUTANEOUS TRANSVENOUS TRANSPLANTATION OF AUTOLOGOUS MYOBLASTS IN THE TREATMENT OF POSTINFARCTION HEART FAILURE; POLYTETRAFLUOROETHYLENE; POZNAN; PTFE; T1D; TOPCARE-AMI; TRANSPLANTATION OF PROGENITOR CELLS AND REGENERATION ENHANCEMENT IN ACUTE MYOCARDIAL INFARCTION; TYPE 1 DIABETES; U.S. FOOD AND DRUG ADMINISTRATION;

CELL- AND TISSUE-BASED THERAPY; HUMANS; UNITED STATES;

EID: 84897576279     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.10.020     Document Type: Review

References (98)

1. Fischbach MA, Bluestone JA, Lim WA. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med. 2013;5(179):179ps7.
2. Preti RA. Bringing safe and effective cell therapies to the bedside. Nat Biotechnol. 2005;23(7):801-804.
3. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4(3):206-216.
4. Smart N, Riley PR. The stem cell movement. Circ Res. 2008;102(10):1155- 1168.
5. Yagi H, Soto-Gutierrez A, Parekkadan B, et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant. 2010;19(6):667-679.
6. Griffith LG, Naughton G. Tissue engineering: current challenges and expanding opportunities. Science. 2002;295(5557):1009-1014.
7. Zhao W, Cui CH, Bose S, et al. Bioinspired multivalent DNA network for capture and release of cells. Proc Natl Acad Sci USA. 2012;109(48):19626-19631.
8. Carlson RH. Quicker bone marrow collection with 'Marrow-Miner' device. Oncol Times. 2009;31(20):29-31.
9. Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum. 2003;48(12):3464-3474.
10. Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106(24):3009-3017.
11. Pharmaceutical Research and Manufacturers of America. Medicines in Development: Biologics, 2013 Report. Washington, DC: Pharmaceutical Research and Manufacturers of America; 2013.
12. Cheng Z, Ou L, Zhou X, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther. 2008;16(3):571-579.
13. Huang J, Zhang Z, Guo J, et al. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res. 2010;106(11):1753-1762.
14. Nir SG, David R, Zaruba M, Franz WM, Itskovitz-Eldor J. Human embryonic stem cells for cardiovascular repair. Cardiovasc Res. 2003;58(2):313-323.
15. Durdu S, Deniz GC, Dogan A, et al. Stem cell mediated cardiovascular repair. Can J Physiol Pharmacol. 2012;90(3):337-351.
16. Dib N, Menasche P, Bartunek JJ, et al. Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC. Cardiovascular Interv. 2010;3(3):265-275.
17. Sherman W, Martens TP, Viles-Gonzalez JF, Siminiak T. Catheter-based delivery of cells to the heart. Nat Clin Pract Cardiovasc Med. 2006;3(suppl 1):S57-S64.
18. Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012;10(3):244-258.
19. Hare JM, Traverse JH, Henry TD, et al. A randomized, doubleblind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54(24):2277-2286.
20. Smits PC, Van Geuns RJ, Poldermans D, et al. Catheter-based intramyocardial injection ofautologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol. 2003;42(12):2063-2069.
21. Assmus B, Honold J, Schachinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006;355(12):1222-1232.
22. Siminiak T, Fiszer D, Jerzykowska O, et al. Percutaneous transcoronary-venous transplantation of autologous skeletal myoblasts in the treatment of post-infarction myocardial contractility impairment: the POZNAN trial. Eur Heart J. 2005;26(12):1188-1195.
23. Vicario J, Campo C, Piva J, et al. One-year follow-up of transcoronary sinus administration of autologous bone marrow in patients with chronic refractory angina. Cardiovasc Revasc Med. 2005;6(3):99-107.
24. Hendrikx M, Hensen K, Clijsters C, et al. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation. 2006;114(1) (suppl):I101-I107.
25. Liu J, Hu Q, Wang Z, et al. Autologous stem cell transplantation for myocardial repair. Am J Physiol. Heart Circ Physiol. 2004;287(2):H501-H511.
26. Teng CJ, Luo J, Chiu RC, Shum-Tim D. Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: implications for cellular cardiomyoplasty. J Thorac Cardiovasc Surg. 2006;132(3):628-632.
27. Hou D, Youssef EA, Brinton TJ, et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation. 2005;112(9) (suppl):I150-I156.
28. Van Der Spoel TI, Vrijsen KR, Koudstaal S, et al. Transendocardial cell injection is not superior to intracoronary infusion in a porcine model of ischaemic cardiomyopathy: a study on delivery efficiency. J Cell Mol Med. 2012;16(11):2768-2776.
29. Musialek P, Tekieli L, Kostkiewicz M, et al. Randomized transcoronary delivery of CD34 (+) cells with perfusion versus stop-flow method in patients with recent myocardial infarction: early cardiac retention of (9) (9) (m) Tc-labeled cells activity. J Nucl Cardiol. 2011;18(1):104-116.
30. Assmus B, Walter DH, Seeger FH, et al. Effect of shock wavefacilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial. JAMA. 2013;309(15):1622-1631.
31. Mahmoudi M, Hosseinkhani H, Hosseinkhani M, et al. Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine. Chem Rev. 2010;111(2):253-280.
32. Penn MS, Ellis S, Gandhi S, et al. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: phase I clinical study. Circ Res. 2012;110(2):304-311.
33. Kharlamov AN, Duckers HJ, Van Beusekom HM, Smits PC, Perin EC, Serruys PW. Do we have a future with transcatheter adventitial delivery of stem cells? Int J Cardiol. 2013;165(2):217-221.
34. Pohl T, Giehrl W, Reichart B, et al. Retroinfusion-supported stenting in high-risk patients for percutaneous intervention and bypass surgery: results of the prospective randomized myoprotect I study. Catheter Cardiovasc Interv. 2004;62(3):323-330.
35. McCall FC, Telukuntla KS, Karantalis V, et al. Myocardial infarction and intramyocardial injection models in swine. Nat Protoc. 2012;7(8):1479-1496.
36. Dib N, Michler RE, Pagani FD, et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation. 2005;112(12):1748-1755.
37. Pompilio G, Steinhoff G, Liebold A, et al. Direct minimally invasive intramyocardial injection of bone marrow-derived AC133+ stem cells in patients with refractory ischemia: preliminary results. Thorac Cardiovasc Surg. 2008;56(2):71-76.
38. Walther T, Simon P, Dewey T, et al. Transapical minimally invasive aortic valve implantation multicenter experience. Circulation. 2007;116(11) (suppl): I-240-I-245.
39. Ota T, Patronik NA, Schwartzman D, Riviere CN, Zenati MA. Minimally invasive epicardial injections using a novel semiautonomous robotic device. Circulation. 2008;118(14) (suppl):S115-S120.
40. Simpson D, Liu H, Fan THM, Nerem R, Dudley SC. A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling. Stem Cells. 2007;25(9):2350-2357.
41. Ladage D, Turnbull IC, Ishikawa K, et al. Delivery of gelfoamenabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model. Gene Ther. 2011;18(10):979-985.
42. Kumar A, Haralampus CA, Hughes M, et al. Assessment of safety, accuracy, and human CD34+ cell retention after intramyocardial injections with a helical needle catheter in a porcine model. Catheter Cardiovasc Interv. 2013;81(6):970-977.
43. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61(23):2329-2338.
44. Haider HK, Lei Y, Ashraf M. MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases. Curr Opin Mol Ther. 2008;10(6):611.
45. Hedman M, Hartikainen J, Ylä-Herttuala S. Progress and prospects: hurdles to cardiovascular gene therapy clinical trials. Gene Ther. 2011;18(8):743-749.
46. Aguado BA, Mulyasasmita W, Su J, Lampe KJ, Heilshorn SC. Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Eng Part A. 2011;18(7-8):806-815.
47. Agashi K, Chau DY, Shakesheff KM. The effect of delivery via narrow-bore needles on mesenchymal cells. Regen Med. 2009;4(1):49-64.
48. Mamidi MK, Singh G, Husin JM, et al. Impact of passing mesenchymal stem cells through smaller bore size needles for subsequent use in patients for clinical or cosmetic indications. J Transl Med. 2012;10(1):1-10.
49. Heng BC, Hsu SH, Cowan CM, et al. Transcatheter injectioninduced changes in human bone marrow-derived mesenchymal stem cells. Cell Transplant. 2009;18(10-11):10-11.
50. Sarkar D, Ankrum JA, Teo GS, Carman CV, Karp JM. Cellular and extracellular programming of cell fate through engineered intracrine-, paracrine-, and endocrine-like mechanisms. Biomaterials. 2011;32(11):3053-3061.
51. Lehmann R, Zuellig RA, Kugelmeier P, et al. Superiority of small islets in human islet transplantation. Diabetes. 2007;56(3):594-603.
52. Jackson DW, Evans NA, Thomas BM. Accuracy of needle placement into the intra-articular space of the knee. J Bone Joint Surg Am. 2002;84(9):1522-1527.
53. Bassett EK, Slocum AH, Masiakos PT, Pryor HI II, Farokhzad OC, Karp JM. Design of a mechanical clutch-based needle-insertion device. Proc Natl Acad Sci U S A. 2009;106(14):5540-5545.
54. Xu C, Miranda-Nieves D, Ankrum JA, et al. Tracking mesenchymal stem cells with iron oxide nanoparticle loaded poly (lactide-coglycolide) microparticles. Nano Lett. 2012;12(8):4131-4139.
55. Cho WK, Ankrum JA, Guo D, et al. Microstructured barbs on the North American porcupine quill enable easy tissue penetration and difficult removal. Proc Natl Acad Sci. 2012;109(52):21289-21294.
56. Keen MF. Comparison of intramuscular injection techniques to reduce site discomfort and lesions. Nurs Res. 1986;35(4):207-210.
57. Mahdavi A, Ferreira L, Sundback C, et al. A biodegradable and biocompatible gecko-inspired tissue adhesive. Proc Natl Acad Sci U S A. 2008;105(7):2307-2312.
58. Pereira MJ, Ouyang B, Sundback CA, et al. A highly tunable biocompatible and multifunctional biodegradable elastomer. Adv Mater. 2013;25(8):1209-1215.
59. Terrovitis J, Lautamaki R, Bonios M, et al. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J Am Coll Cardiol. 2009;54(17):1619-1626.
60. Sitzman BT, Uncles DR. The effects of needle type, gauge, and tip bend on spinal needle deflection. Anesth Analg. 1996;82(2):297-301.
61. Walsh CJ, Franklin J, Slocum AH, Gupta R. Design of a robotic tool for percutaneous instrument distal tip repositioning. Paper presented at: 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society; August 30-September 3, 2011; Boston, MA.
62. Potts MB, Silvestrini MT, Lim DA. Devices for cell transplantation into the central nervous system: design considerations and emerging technologies. Surg Neurol Int. 2013;4(suppl 1):S22.
63. Sears P, Dupont P. A steerable needle technology using curved concentric tubes. Paper presented at: 2006 IEEE/RSJ International Conference on Intelligent Robots and Systems; October 9-15, 2006; Beijing, China.
64. Wu SM, Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol. 2011;13(5):497-505.
65. Orive G, Hernandez RM, Gascon AR, et al. Cell encapsulation: promise and progress. Nat Med. 2003;9(1):104-107.
66. Birch DG, Weleber RG, Duncan JL, Jaffe GJ, Tao W. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am J Ophthalmol. 2013;156(2):283-292.e1.
67. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A. 2006;103(10):3896-3901.
68. O'Connell SM, Cooper MN, Bulsara MK, Davis EA, Jones TW. Reducing rates of severe hypoglycemia in a population-based cohort of children and adolescents with type 1 diabetes over the decade 2000-2009. Diabetes Care. 2011;34(11):2379-2380.
69. Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ, Harlan DM. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA. 2003;290(21):2817-2823.
70. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes. 1967;16(1):35-39.
71. Shapiro AJ, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoidfree immunosuppressive regimen. N Engl J Med. 2000;343(4):230-238.
72. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54(7):2060-2069.
73. Yi P, Park J-S, Melton DA. Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell. 2013;153(4):747-758.
74. Kroon E, Martinson LA, Kadoya K, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucoseresponsive insulin-secreting cells in vivo. Nat Biotechnol. 2008;26(4):443-452.
75. Maehr R, Chen S, Snitow M, et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci. 2009;106(37):15768- 15773.
76. Edgerton DS, Lautz M, Scott M, et al. Insulin's direct effects on the liver dominate the control of hepatic glucose production. J Clin Investig. 2006;116(2):521-527.
77. Low G, Hussein N, Owen RJ, et al. Role of imaging in clinical islet transplantation. Radiographics. 2010;30(2):353-366.
78. Noguchi H, Yamada Y, Okitsu T, et al. Secretory unit of islet in transplantation (SUIT) and engrafted islet rate (EIR) indexes are useful for evaluating single islet transplantation. Cell Transplant. 2008;17(1-2):1-2.
79. Hillberg AL, Kathirgamanathan K, Lam JB, Law LY, Garkavenko O, Elliott RB. Improving alginate-poly-L-ornithinealginate capsule biocompatibility through genipin crosslinking. J Biomed Mater Res B Appl Biomater. 2013;101(2):258-268.
80. Geller RL, Loudovaris T, Neuenfeldt S, Johnson RC, Brauker JH. Use of an immunoisolation device for cell transplantation and tumor immunotherapy. Ann N Y Acad Sci. 1997;831(1):438-451.
81. Garkavenko O, Wynyard S, Nathu D, et al. The first clinical xenotransplantation trial in New Zealand: efficacy and safety. Xenotransplantation. 2012;19(1):6-7.
82. Grose S. Critics slam Russian trial to test pig pancreas for diabetics. Nat Med. 2007;13(4):390-391.
83. Ratner M. Shire punts on bioscaffolds for cell-based regenerative medicine. Nat Biotechnol. 2012;30(8):727-728.
84. Storrs R, Dorian R, King SR, Lakey J, Rilo H. Preclinical development of the islet sheet. Ann N Y Acad Sci. 2001;944(1):252-266.
85. Ludwig B, Rotem A, Schmid J, et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci U S A. 2012;109(13):5022-5027.
86. Furlani D, Ugurlucan M, Ong L, et al. Is the intravascular administration of mesenchymal stem cells safe? mesenchymal stem cells and intravital microscopy. Microvasc Res. 2009;77(3):370-376.
87. Darabi K, Brown JR, Kao GS. Paradoxical embolism after peripheral blood stem cell infusion. Bone Marrow Transplant. 2005;36(6):561-562.
88. Breitbach M, Bostani T, Roell W, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007;110(4):1362-1369.
89. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003;9(6):702-712.
90. Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009;6(2):e1000029.
91. Jezek J, Darton NJ, Derham BK, Royle N, Simpson I. Biopharmaceutical formulations for pre-filled delivery devices. Expert Opin Drug Deliv. 2013;10(6):811-828.
92. Yakhnenko I, Wong WK, Katkov II, Itkin-Ansari P. Cryopreservation of human insulin expressing cells macro-encapsulated in a durable therapeutic immunoisolating device theracyte. Cryo Lett. 2012;33(6):518-531.
93. Hanna J, Hubel A. Preservation of stem cells. Organogenesis. 2009;5(3):134-137.
94. Hubel A. Advancing the preservation of cellular therapy products. Transfusion. 2011;51(suppl 4):82S-86S.
95. Kuleshova LL, Gouk SS, Hutmacher DW. Vitrification as a prospect for cryopreservation of tissue-engineered constructs. Biomaterials. 2007;28(9):1585-1596.
96. Coelho MB, Cabral JM, Karp JM. Intraoperative stem cell therapy. Annu Rev Biomed Eng. 2012;14:325-349.
97. Ghodsizad A, Klein H-M, Borowski A, et al. Intraoperative isolation and processing of BM-derived stem cells. Cytotherapy. 2004;6(5):523-526.
98. Kolvenbach R, Kreissig C, Cagiannos C, Afifi R, Schmaltz E. Intraoperative adjunctive stem cell treatment in patients with critical limb ischemia using a novel point-of-care device. Ann Vasc Surg. 2010;24(3):367-372.